Rockwell Medical Technologies receives FDA OK for drug-delivery product
Rockwell Medical Technologies, Inc. (Nasdaq: RMTI), a manufacturer and developer of renal drug therapies and essential dialysate products, reported today that the FDA has approved initiation of a National Institutes of Health (NIH) sponsored clinical study for its proprietary drug-delivery product SFP for chronic hemodialysis patients.
SFP is a water soluble form of iron designed to provide physiological-iron-maintenance-therapy for anemic ESRD patients
Shares of Rockwell Medical (RMTI) were halted in pre-market trading.
